Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beyond Herceptin: Kadcyla Carries Torch Across Lines Of HER2 Therapy

Executive Summary

Genentech’s HER2 program director Dietmar Berger shares broader plans for Kadcyla (ado-trastuzumab emtansine) following its approval in second-line mBC, and expects Herceptin will continue to play a role in the long term.

You may also be interested in...

Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer

KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.

Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line

Roche posted solid 2012 results and development of new cancer drugs continues apace, forecasting further sales and profit gains in 2013 and beyond – as long as government insurers can handle the abundance.

Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use

FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts